Zibotentan
Term · Oncology and biomedicine · MLC-T-ONC-009476
A substance being studied in the treatment of some types of cancer. Zibotentan may block cancer cell growth. It is a type of endothelin-A receptor antagonist.
An orally available selective antagonist of the endothelin-A (ET-A) receptor with potential antineoplastic activity. Zibotentan binds selectively to the ET-A receptor, thereby inhibiting endothelin-mediated mechanisms that promote tumor cell proliferation.
| Identifier | MLC-T-ONC-009476 |
|---|---|
| Field | Oncology and biomedicine |
| References | NCI Dictionary of Cancer Terms; National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-009476",
"term": "Zibotentan",
"field": "Oncology and biomedicine",
"definitions": [
"A substance being studied in the treatment of some types of cancer. Zibotentan may block cancer cell growth. It is a type of endothelin-A receptor antagonist.",
"An orally available selective antagonist of the endothelin-A (ET-A) receptor with potential antineoplastic activity. Zibotentan binds selectively to the ET-A receptor, thereby inhibiting endothelin-mediated mechanisms that promote tumor cell proliferation."
],
"references": [
"NCI Dictionary of Cancer Terms",
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/zibotentan/"
}
Record 17,625 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.